Comparative Pharmacology
Head-to-head clinical analysis: PENTAMIDINE ISETHIONATE versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTAMIDINE ISETHIONATE versus SATRIC.
PENTAMIDINE ISETHIONATE vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentamidine isethionate is a synthetic aromatic diamidine that interferes with protozoal DNA replication, transcription, and RNA processing. Its exact mechanism is unclear but may involve inhibition of dihydrofolate reductase, interference with polyamine synthesis, and binding to kinetoplast DNA.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Treatment of Pneumocystis jirovecii pneumonia (PCP): 4 mg/kg IV once daily for 21 days. Chemoprophylaxis of PCP: 300 mg inhalation via nebulizer every 4 weeks, or 4 mg/kg IV every 2-4 weeks. Treatment of leishmaniasis: 2-4 mg/kg IM or IV once daily or every other day for 14-30 doses.
No standard dosing information available for SATRIC.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; prolongs to >48 hours in renal impairment, necessitating dose adjustment.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Renal excretion accounts for approximately 60-70% of elimination, primarily as unchanged drug. Biliary/fecal elimination constitutes 10-20%, with the remainder undergoing metabolic clearance.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category A/B
Category C
Antiprotozoal
Antiprotozoal, Antibiotic